Government and private health-care program payers have been anxiously awaiting FDA action on biosimilars. Payers anticipate that the ability to substitute and dispense a biosimilar product in lieu of a more expensive prescribed biologic or specialty drug may save payment programs millions, if not billions, of dollars.
In order to freely substitute a biosimilar for a prescribed reference biological product, the FDA must determine that the biosimilar is interchangeable with the reference product.
Originally published in BNA’s Medicare Report on May 29, 2015.
Please see full publication below for more information.